2. Search Result
Search Result
Results for "

β1-integrin

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

3

Biochemical Assay Reagents

18

Peptides

2

Inhibitory Antibodies

2

Natural
Products

11

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100506
    GLPG0187
    Maximum Cited Publications
    18 Publications Verification

    		 Integrin Cancer
    GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM [1]. GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
    GLPG0187
  • HY-13306
    Pyrintegrin
    4 Publications Verification

    		 Integrin Metabolic Disease
    Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic [1] .
    Pyrintegrin
  • HY-137561
    Bexotegrast
    3 Publications Verification

    PLN-74809

    		 Integrin Inflammation/Immunology
    Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung [1] .
    Bexotegrast
  • HY-134130
    Integrin modulator 1
    2 Publications Verification

    		 Integrin Inflammation/Immunology
    Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM [1].
    Integrin modulator 1
  • HY-112055
    DIM-C-pPhOH
    5+ Cited Publications

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis Cancer
    DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively [1].
    DIM-C-pPhOH
  • HY-15770
    TR-14035
    5+ Cited Publications

    		 Integrin Inflammation/Immunology
    TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases [1] .
    TR-14035
  • HY-P0204A
    Endothelin-3, human, mouse, rabbit, rat TFA
    1 Publications Verification

    Endothelin 3 (Rat,Human) TFA

    		 Endothelin Receptor Integrin Neurological Disease
    Endothelin-3, human, mouse, rabbit, rat TFA (Endothelin 3 (Rat,Human) TFA) is an adhesion stimulant. Endothelin-3, human, mouse, rabbit, rat TFA stimulates the adhesion of enteric neural crest cells to various ECM components. Endothelin-3, human, mouse, rabbit, rat TFA plays an important role in the maintenance and self-renewal of intestinal progenitor cells, participates in the migration of enteric neural crest cells, and helps maintain a suitable environment for the colonization of enteric neural crest cells. Endothelin-3, human, mouse, rabbit, rat TFA acts synergistically with the β1-integrin signaling pathway during enteric nervous system development. Endothelin-3, human, mouse, rabbit, rat TFA can be used in studies related to distal aganglionosis [1].
    Endothelin-3, human, mouse, rabbit, rat TFA
  • HY-P1408
    Obtustatin
    4 Publications Verification

    		 Integrin VEGFR Cancer
    Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma [1] .
    Obtustatin
  • HY-100445A
    αvβ1 integrin-IN-1 TFA
    5+ Cited Publications

    		 Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects [1].
    αvβ1 integrin-IN-1 TFA
  • HY-N2587
    Irigenin

    		Integrin Apoptosis Cancer
    Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells [1].
    Irigenin
  • HY-175287
    α5β1 integrin agonist-2

    		Integrin Cancer
    α5β1 integrin agonist-2 (Compound 2) is a selective α5β1 integrin agonist (EC50 = 45.98 nM). α5β1 integrin agonist-2 induces integrin activation. α5β1 integrin agonist-2 is applicable to the research of leukemia [1].
    α5β1 integrin agonist-2
  • HY-P2267
    LDV
    1 Publications Verification

    		 Integrin Others
    LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells [1] .
    LDV
  • HY-100445
    αvβ1 integrin-IN-1
    5+ Cited Publications

    		 Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects [1].
    αvβ1 integrin-IN-1
  • HY-P11328
    GFOGER peptide

    		Integrin Others
    GFOGER peptide is an artificially synthesized collagen-mimetic sequence. GFOGER peptide acts as a ligand for α2β1, α11β1 and α1β1 integrins, thereby supporting integrin-mediated cell adhesion to collagen. GFOGER peptide triggers signaling pathways mediated by the α2β1 integrin receptor and upregulates osteoblast differentiation. GFOGER peptide accelerates and enhances bone formation at sites of refractory femoral defects. GFOGER peptide can be passively adsorbed onto polymer scaffolds for cell-free/growth factor-free bone formation. GFOGER peptide is used in biomaterials such as hydrogels and 3D bioinks for tissue engineering research including bone formation [1] .
    GFOGER peptide
  • HY-P1868
    α2β1 Integrin Ligand Peptide
    3 Publications Verification

    DGEA peptide

    		 Integrin Infection
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors [1].
    α2β1 Integrin Ligand Peptide
  • HY-P0204
    Endothelin-3, human, mouse, rabbit, rat
    1 Publications Verification

    Endothelin 3 (Rat,Human)

    		 Endothelin Receptor Integrin Neurological Disease
    Endothelin-3, human, mouse, rabbit, rat (Endothelin 3 (Rat,Human)) is an adhesion stimulant. Endothelin-3, human, mouse, rabbit, rat stimulates the adhesion of enteric neural crest cells to various ECM components. Endothelin-3, human, mouse, rabbit, rat plays an important role in the maintenance and self-renewal of intestinal progenitor cells, participates in the migration of enteric neural crest cells, and helps maintain a suitable environment for the colonization of enteric neural crest cells. Endothelin-3, human, mouse, rabbit, rat acts synergistically with the β1-integrin signaling pathway during enteric nervous system development. Endothelin-3, human, mouse, rabbit, rat can be used in studies related to distal aganglionosis [1].
    Endothelin-3, human, mouse, rabbit, rat
  • HY-150124
    K34c

    		Integrin Apoptosis Cancer
    K34c is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c can be used in glioblastoma research [1].
    K34c
  • HY-139702
    α5β1 integrin agonist-1

    		Integrin Apoptosis Caspase Cancer
    α5β1 integrin agonist-1 is an α5β1 integrin agonist, with an EC50 of 1.5 nM. α5β1 integrin agonist-1 inhabits α4β1 integrin (IC50 = 2.99 μM) in Jurkat/VCAM-1 adhesion assayα5β1 integrin agonist-1 induces concentration-dependent apoptosis and activates the caspase 3/7 pathway in α5β1 integrin-expressing K562 cancer cells. α5β1 integrin agonist-1 can be used for the study of cancer [1].
    α5β1 integrin agonist-1
  • HY-78263
    MNS
    3 Publications Verification

    NSC 170724; 5-(2-Nitrovinyl)benzodioxole

    		 Src Syk NOD-like Receptor (NLR) Integrin PANoptosis Neurological Disease Inflammation/Immunology Cancer
    MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells [1] .
    MNS
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA
    3 Publications Verification

    DGEA peptide TFA

    		 Integrin Others
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors [1].
    α2β1 Integrin Ligand Peptide TFA
  • HY-129453
    BOP sodium

    		Integrin Inflammation/Immunology
    BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins [1] .
    BOP sodium
  • HY-P5812
    IDR 1002

    		Integrin Inflammation/Immunology
    IDR-1002 is an anti-infective peptide that enhances the ability of human monocytes to migrate toward chemokines on fibronectin. IDR-1002 also induces adhesion and activation of β1-integrin, a mechanism that promotes monocyte recruitment [1].
    IDR 1002
  • HY-P1188
    LDV-FITC

    		Integrin Cancer
    LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity [1] .
    LDV-FITC
  • HY-P10941A
    VSLRGDTRG acetate

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG acetate is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG acetate promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG acetate can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer [1] .
    VSLRGDTRG acetate
  • HY-111413A
    c(phg-isoDGR-(NMe)k) TFA

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM [1].
    c(phg-isoDGR-(NMe)k) TFA
  • HY-164768
    LT25

    		Integrin Cancer
    LT25 (compound 17) is a agonist of α5β1 integrin with EC50 value of 9.9 nM [1].
    LT25
  • HY-P10941
    VSLRGDTRG

    		Integrin FAK ERK Inflammation/Immunology Cancer
    VSLRGDTRG is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer [1] .
    VSLRGDTRG
  • HY-161730
    αvβ1 integrin-IN-3

    		Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect [1].
    αvβ1 integrin-IN-3
  • HY-P4866
    Q-Peptide

    		Integrin Transglutaminase Akt p38 MAPK ERK Caspase Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Q-Peptide is an angiopoietin-1 derived peptide (QHREDGS). Q-Peptide interacts with β1-integrin, binds to integrins on the surface of osteoblasts, and serves as an acyl donor substrate for Streptomyces mobaraensis transglutaminase. Q-Peptide activates Akt, MAPKp42/44, ILK, ERK1/2, and downregulates caspase-3/7. Q-Peptide inhibits cell apoptosis, enhances cell adhesion and migration, and promotes osteoblast differentiation, bone matrix deposition and mineralization. Q-Peptide can be used in studies related to myocardial infarction, bone regeneration, diabetic wound repair and human induced pluripotent stem cells [1] .
    Q-Peptide
  • HY-150124A
    K34c hydrochloride

    		Integrin Apoptosis Cancer
    K34c hydrochloride is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c hydrochloride reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c hydrochloride can be used in glioblastoma research [1].
    K34c hydrochloride
  • HY-177331
    BTT-3034

    		Integrin Cardiovascular Disease
    BTT-3034, a sulfonamide derivative, is an α2β1 integrin inhibitor. BTT-3034 inhibits cell adhesion to rat tail collagen I with an EC50 of 160 nM and a corresponding Emaxof 86%. BTT-3034 inhibits collagen binding by an α2 variant carrying the conformationally activating E318W mutation [1].
    BTT-3034
  • HY-48959
    α7β1 integrin modulator-1

    		Integrin Metabolic Disease
    α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy [1].
    α7β1 integrin modulator-1
  • HY-P10984
    FNIII14

    		Integrin Metabolic Disease Inflammation/Immunology Cancer
    FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in β1-integrin from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors [1].
    FNIII14
  • HY-111413
    c(phg-isoDGR-(NMe)k)

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM [1].
    c(phg-isoDGR-(NMe)k)
  • HY-P5038
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)

    c(GRGDSP)

    		 Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells [1].
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-P5929
    VnP-16

    		Integrin FAK Inflammation/Immunology
    VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation [1].
    VnP-16
  • HY-P991652
    MINT1526A

    RG-7594

    		 Integrin Cancer
    MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research [1].
    MINT1526A
  • HY-P10993
    CT20p

    		Bcl-2 Family Cancer
    CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer [1].
    CT20p
  • HY-175286
    α4β1 antagonist-1

    		Integrin ERK Inflammation/Immunology Cancer
    α4β1 antagonist-1 (Compound 4) is a highly selective α4β1 integrin antagonist (IC50=15 nM). α4β1 antagonist-1 inhibits integrin-mediated cell adhesion and ERK1/2 signaling activation. α4β1 antagonist-1 also exhibits partial agonism toward αMβ2 integrin (EC50=23 nM). α4β1 antagonist-1 is promising for research of chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancers [1].
    α4β1 antagonist-1
  • HY-136214
    R-BC154 acetate

    		Integrin Inflammation/Immunology Cancer
    R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity [1].
    R-BC154 acetate
  • HY-P1188A
    LDV-FITC TFA

    		Integrin Cancer
    LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity [1] .
    LDV-FITC TFA
  • HY-123802
    BIO7662

    		Integrin Cancer
    BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions [1] .
    BIO7662
  • HY-119142
    CP-664511

    		Integrin Inflammation/Immunology
    CP-664511 is an orally active and potent α4β1 integrin antagonist with anti-inflammatory effects (IC50=0.52 nM). CP-664511 inhibits the interaction between α4β1 and vascular cell adhesion molecule-1 (VCAM-1), significantly reducing eosinophil infiltration into lung tissue. CP-664511 is promising for research of asthma and allergic airway diseases [1].
    CP-664511
  • HY-N2587R
    Irigenin (Standard)

    		Reference Standards Integrin Apoptosis Cancer
    Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells [1].
    Irigenin (Standard)
  • HY-NP216
    PA-IIL

    LecB

    		 Integrin Endogenous Metabolite Bacterial Infection
    PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection [1] .
    PA-IIL
  • HY-122585
    proMMP-9 inhibitor-3c

    		MMP Src FAK Cancer
    proMMP-9 inhibitor-3c (compound 3c) is a potent proMMP-9 inhibitor. proMMP-9 inhibitor-3c is specific for binding to the proMMP-9 hemopexin-like domain (Kd=320 nM). proMMP-9 inhibitor-3c disruption of MMP-9 homodimerization prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. This disruption results in decreased phosphorylation of Src and its downstream target proteins focal adhesion kinase (FAK) and paxillin (PAX) [1].
    proMMP-9 inhibitor-3c
  • HY-100506R
    GLPG0187 (Standard)

    		Integrin Reference Standards Cancer
    GLPG0187 (Standard) is the analytical standard of GLPG0187 (HY-100506). This product is intended for research and analytical applications. GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM [1]. GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
    GLPG0187 (Standard)
  • HY-180057
    α5β1 integrin-IN-1

    		Integrin Inflammation/Immunology
    α5β1 integrin-IN-1 (compound 65) is a potent and selective α5β1 integrin inhibitor with a pIC50 of 9.4. α5β1 integrin-IN-1 displays >10000-fold selectivity for α5β1 over αVβ3 (pIC50 = 5.5). α5β1 integrin-IN-1 reduces airway smooth muscle (ASM) tension through the disruption of cellular tethering. α5β1 integrin-IN-1 exhibits excellent inhalation pharmacokinetics in rodent. α5β1 integrin-IN-1 can be used for asthma research [1].
    α5β1 integrin-IN-1
  • HY-P11649
    NYLTHRQ

    		Integrin VEGFR Cancer
    NYLTHRQ is a peptide. NYLTHRQ specifically blocks the interaction between sVEGFR1-i13 and β1 integrin, and inhibits the activation of VEGFR1 and VEGFR2. NYLTHRQ inhibits cancer cell proliferation. NYLTHRQ can be used in the research of tumors such as lung squamous cell carcinoma [1].
    NYLTHRQ
  • HY-P992436
    PAS-003

    		Integrin Neurological Disease
    PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis [1].
    PAS-003

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: